TG 02 - Targovax

Drug Profile

TG 02 - Targovax

Alternative Names: TG02 - Targovax

Latest Information Update: 05 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Targovax
  • Class Antineoplastics; Cancer vaccines; Peptide vaccines
  • Mechanism of Action Cytotoxic T lymphocyte stimulants; Helper-inducer T-lymphocyte stimulants; Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase I Rectal cancer
  • Preclinical Colorectal cancer; Non-small cell lung cancer

Most Recent Events

  • 03 Oct 2017 Targovax has patent protection for TG 02 (mutant-RAS specific neoantigen vaccines) in USA
  • 25 Sep 2017 Targovax has patent protection for TG 02 (mutant-RAS specific neoantigen vaccines) in USA
  • 01 Sep 2016 Phase-Ib clinical trials in Rectal cancer (Combination therapy, Recurrent) in Australia (Parenteral) (NCT02933944)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top